Yu Wing Tak Wendy Purchases Shares of Niagen Bioscience
Yu Wing Tak Wendy acquired 31,746 shares of Niagen Bioscience on June 24, 2026.
Key Points
- Yu Wing Tak Wendy bought 31,746 shares of Niagen Bioscience, Inc. (NAGE) on June 24, 2026.
- Shares of NAGE traded near $3.42 on Saturday with a market cap of $272.4 million.
- Insider buying activity included several executives, with analysts maintaining a positive outlook on the stock.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Yu Wing Tak Wendy made a move in the stock market by purchasing 31,746 shares of Niagen Bioscience, Inc. (NasdaqCM: NAGE) on June 24, 2026. This transaction was not part of a pre-planned trading scheme, indicating a direct decision to invest in the company.
Insider Buying and Selling at Niagen Bioscience, Inc.
On the same day, several other insiders, including Frank Jaksch Jr., Ng Wang Yu Gary, Ann Cohen, Kristin Patrick, Steven Rubin, and Hamed Shahbazi, also bought 31,746 shares each. These transactions were similarly unplanned, suggesting a coordinated move among the company's leadership.
Niagen Bioscience, Inc. Stock Up 4.0%
Shares of Niagen Bioscience traded near $3.42 on Saturday. The company boasts a market capitalization of approximately $272.4 million and a P/E ratio of 16.29. With a beta of 2.06, the stock has shown volatility. Over the past year, the stock has ranged from a low of $3.29 to a high of $14.69. It has a 50-day moving average of $3.99 and a 200-day moving average of $5.83. The company maintains a healthy current ratio of 4.61 and a quick ratio of 3.48, although its debt-to-equity ratio is relatively high at 3.13.
$NAGE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have maintained a favorable outlook on Niagen Bioscience. On May 11, 2026, HC Wainwright & Co. maintained their 'buy' rating with a price target of $11. Canaccord Genuity also maintained a 'buy' rating with a target of $10 on May 5, 2026. The consensus among analysts is positive, with a mean target price of $12.60 based on five opinions.
About Niagen Bioscience
Niagen Bioscience, Inc. is a biotechnology company based in Los Angeles, California. It focuses on developing products for healthy aging, including dietary supplements and pharmaceutical-grade ingredients. The company is led by CEO Robert N. Fried and employs about 117 people. Its flagship product, NIAGEN, is a nicotinamide riboside ingredient that supports cellular metabolism. Niagen Bioscience sells its products directly to consumers through its e-commerce platform and other online marketplaces.
Bottom Line
The insider buying activity at Niagen Bioscience highlights confidence among its executives. Investors often watch such moves for potential signals about a company's future. While these transactions are insightful, they represent past actions and should be considered as part of a broader investment strategy.
Get Niagen Bioscience, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NAGE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.